FLUniversal brings together world-leading experts with tools and knowledge to further develop DeltaFLU, a novel universal #influenza vaccine. DeltaFLU already has surmounted key hurdles of novel vaccines: demonstration of safety and robust immunogenicity in humans and manufacturability. The FLUniversal programme is a synergistic combination of preclinical models, a controlled human infection model (CHIM) for #clinicaltrials, clinical samples, and integrated complex immunological analyses to identify molecular signatures of protection and reduce the timeline and risks involved in clinical development.